A Randomised Phase II Double Blind Placebo Controlled Trial of Whole Brain Radiotherapy (WBRT) and Tarceva (OSI-774, Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Multiple Brain Metastases
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Erlotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TACTIC
- 28 Oct 2013 Primary endpoint 'Progression-free-survival-rate' has not been met.
- 28 Oct 2013 Status changed from active, no longer recruiting to completed.
- 31 May 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.